Novartis in up to $2.9 billion licensing deal for PTC Therapeutics Huntington's disease drug
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological disorder called Huntington's disease, sending the U.S.-based biotech's shares up about 14% on Monday.
Novartis failed to persuade a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' ...
Switzerland-based Novartis has one of the strongest and broadest portfolios of varied drugs that has enabled it to maintain its dominant position as a top pharma company over the years. It continues ...
HSBC analyst Rajesh Kumar downgraded Novartis (NVS) to Reduce from Hold with a price target of CHF 82, down from CHF 95. The firm calls the ...
Fmr LLC grew its position in shares of Novartis AG (NYSE:NVS – Free Report) by 5.5% during the 3rd quarter, Holdings ...
Novartis has announced the acquisition of San Diego-based Kate Therapeutics in a deal valued at $1.1bn, enhancing its ...
Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the three recipients of its inaugural Health Equity ...
US biopharma Olema Pharmaceuticals has announced a clinical trial collaboration and supply agreement with Swiss pharma giant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback